Greenland Mines (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis ("ALS") and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. This development underscores Greenland Mines' commitment to securing broad patent protection for its gene therapy platform, which could have significant implications for the treatment of neurodegenerative diseases that currently have limited therapeutic options.
Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year. The progression of these candidates toward manufacturing and regulatory discussions marks a critical step in translating the patented technology into potential therapies for patients.
The patent grant strengthens Greenland Mines' position in the competitive field of gene therapy for neurological conditions. By securing intellectual property rights in Canada, the company not only protects its innovations but also establishes a foothold in a key market. This could enhance its ability to form partnerships or attract investment for further development of its Klotho-based programs.
For more details on the patent and the company's pipeline, the full press release is available at https://ibn.fm/x2pHAA. Investors and stakeholders can also follow the latest news and updates relating to GRML in the company's newsroom at https://ibn.fm/GRML.
This announcement highlights the potential of Klotho-based therapies to address a range of neurological disorders, a field with significant unmet medical need. The patent protection may also provide Greenland Mines with a competitive advantage as it advances its candidates through development and toward potential commercialization. However, as with all early-stage biotech developments, there are inherent risks and uncertainties, and the company's forward-looking statements should be considered in light of these factors.
